Literature DB >> 19933901

Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time.

Jean-Yves Douillard.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19933901     DOI: 10.1200/JCO.2009.25.5109

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.

Authors:  Jun Zhang; Ning Chen; Juan Qi; Baosen Zhou; Xueshan Qiu
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-27       Impact factor: 4.553

Review 2.  Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.

Authors:  Maria Bonomi; Sara Pilotto; Michele Milella; Francesco Massari; Sara Cingarlini; Matteo Brunelli; Marco Chilosi; Giampaolo Tortora; Emilio Bria
Journal:  J Exp Clin Cancer Res       Date:  2011-12-29

3.  [Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer].

Authors:  Jun Zhang; Juan Qi; Yan Guo; Yi Guo; Weineng Fu; Baosen Zhou; Guangping Wu; Libo Han; Anguang He
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-03

4.  High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer.

Authors:  Jun Zhang; Juan Qi; Ning Chen; Weineng Fu; Baosen Zhou; Anguang He
Journal:  Oncol Lett       Date:  2013-02-22       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.